RYTM (Rhythm Pharmaceuticals) Shiller PE Ratio: (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RYTM Rhythm Pharmaceuticals Inc RYTM
56 GF Score
Price $116.31
GF Value $119.19
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Rhythm Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Rhythm Pharmaceuticals  (NAS:RYTM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Rhythm Pharmaceuticals Shiller PE Ratio Related Terms


Rhythm Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Rhythm Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Pharmaceuticals Shiller PE Ratio Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rhythm Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RYTM vs MIRM, COGT, ERAS: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Rhythm Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's Shiller PE Ratio falls into.


RYTM
56GF Score
Rhythm Pharmaceuticals Inc RYTM
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Rhythm Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Rhythm Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.73/333.9520*333.9520
=-0.730

Current CPI (Jun. 2026) = 333.9520.

Rhythm Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.430 241.428 -0.595
201612 -0.548 241.432 -0.758
201703 -0.450 243.801 -0.616
201706 -0.307 244.955 -0.419
201709 -0.438 246.819 -0.593
201712 -0.410 246.524 -0.555
201803 -0.600 249.554 -0.803
201806 -0.520 251.989 -0.689
201809 -0.520 252.439 -0.688
201812 -0.740 251.233 -0.984
201903 -0.840 254.202 -1.104
201906 -1.240 256.143 -1.617
201909 -1.040 256.759 -1.353
201912 -0.780 256.974 -1.014
202003 -0.780 258.115 -1.009
202006 -0.710 257.797 -0.920
202009 -0.770 260.280 -0.988
202012 -0.790 260.474 -1.013
202103 0.900 264.877 1.135
202106 -0.700 271.696 -0.860
202109 -0.700 274.310 -0.852
202112 -0.850 278.802 -1.018
202203 -1.050 287.504 -1.220
202206 -0.890 296.311 -1.003
202209 -0.790 296.808 -0.889
202212 -0.750 296.797 -0.844
202303 -0.920 301.836 -1.018
202306 -0.820 305.109 -0.898
202309 -0.760 307.789 -0.825
202312 -0.700 306.746 -0.762
202403 -2.350 312.332 -2.513
202406 -0.550 314.175 -0.585
202409 -0.730 315.301 -0.773
202412 -0.720 315.605 -0.762
202503 -0.810 319.799 -0.846
202506 -0.750 322.561 -0.776
202509 -0.820 324.800 -0.843
202512 -0.730 324.054 -0.752
202603 -0.830 330.213 -0.839
202606 -0.730 333.952 -0.730

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Rhythm Pharmaceuticals (RYTM) Overvalued in 2026?

Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued. The current stock price of $116.31 is trading 2.4% below its estimated GF Value™ of $119.19. GuruFocus considers Rhythm Pharmaceuticals to be Fairly Valued.

Key valuation signals for RYTM:

  • Shiller PE Ratio:
  • GF Value™: $119.19 vs. price of $116.31 (2.4% below fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rhythm Pharmaceuticals Business Description

Other Exchanges 1RV:Germany
Address 222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score

Get the complete analysis for RYTM

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$116.31
Price
$119.19
GF Value